Insurance Gaps Threaten Cancer Treatment Success
July 7th 2025Access to and affordability of immune checkpoint inhibitors, which can be lifesaving if patients receive them on time and under optimal circumstances, continue to top the list of reasons behind outcomes disparities for patients who have private insurance vs those who remain uninsured.
Read More
Higher Infection Risk With Venetoclax-Obinutuzumab vs Zanubrutinib in CLL/SLL
July 7th 2025Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) treated with venetoclax plus obinutuzumab experienced significantly higher rates of serious infections compared with those receiving zanubrutinib, according to real-world data.
Read More
Depemokimab Reduces Exacerbations Regardless of Baseline Asthma Control
July 3rd 2025Depemokimab significantly reduces asthma exacerbations, benefiting patients regardless of their baseline asthma control levels. A biologics license application for depemokimab is currently being reviewed by the FDA.
Read More
Racial Disparities in Opioid Use Disorder Treatment After ED Visit for Overdose
July 2nd 2025There are significant racial disparities in outpatient referrals for opioid use disorder treatment, highlighting urgent need for targeted interventions in emergency care, according to a recent study.
Read More
Medina v Planned Parenthood Case Reinterprets Any Willing Provider Provision: Jennifer Evans, JD
July 2nd 2025The Supreme Court decision in Medina v Planned Parenthood interprets the Social Security Acts Medicaid provision as not being able to be enforced by an individual, according to Jennifer Evans, JD.
Watch
AZD0486 demonstrated encouraging safety and dose-dependent efficacy in heavily pretreated adolescent and adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL), according to early findings from the phase 1/2 SYRUS trial and Ibrahim Aldoss, MD, of City of Hope.
Watch